Heart failure & cardiomyopathies
Reductions in Renin-Angiotensin System Inhibitors Following Hospitalization for Heart Failure
Authors' conclusion
In contrast to RASI discontinuation, RASI dose-reduction was not associated with adverse short or long-term outcomes.
Study context
- Population
- Older adults with HFrEF treated with renin-angiotensin system inhibitor (RASI) before hospitalization, discharged home after HFrEF hospitalization, 2007–2018
- Participants
- 12,794 adults
- Exposure
- RASI dose-reduction or discontinuation vs same/increased dose after HF hospitalization
- Outcome
- Mortality and all-cause readmission
- Follow-up
- 30 days and 1 year
Methodological details5% random sample of Medicare beneficiaries
- 5% random sample of Medicare beneficiaries
Main finding
As reported in the abstract
Observational data: associations, not effects.
Original publication
Reductions in Renin-Angiotensin System Inhibitors Following Hospitalization for Heart Failure. ESC Heart Fail. Published 19 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →